Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Case Comprehensive Cancer Center13 enrolled

Overview

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic colorectal cancer.

OBJECTIVES: * Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine. * Evaluate tumor tissue biochemical and immunohistochemical predictors of response in patients treated with this regimen. * Correlate carcinoembryonic antigen levels in the peripheral blood with response in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive O6-benzylguanine (BG) IV over 1 hour and carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study within 1.7-3 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

O6-benzylguanineDRUG

Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.

carmustineDRUG

Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of metastatic colorectal carcinoma * Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * WBC at least 4,000/mm\^3 * Granulocyte count at least 1,500/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin greater than 8 g/dL Hepatic: * Bilirubin no greater than 1.2 mg/dL * AST and ALT less than 2.5 times upper limit of normal (ULN) * PT no greater than ULN (not on anticoagulation therapy) Renal: * Creatinine no greater than 1.5 mg/dL * Creatine clearance greater than 60 mL/min Pulmonary: * DLCO at least 60% Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 2 months after study * No other concurrent active malignancies * Prior malignancies presumed to be cured allowed * No other concurrent uncontrolled severe medical problem that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 6 months since prior adjuvant chemotherapy without disease recurrence * No more than 1 prior chemotherapy regimen for metastatic disease Endocrine therapy: * Not specified Radiotherapy: * Prior adjuvant radiotherapy allowed * No prior radiotherapy to more than 25% of total bone marrow Surgery: * Not specified Other: * No other prior therapy for advanced disease

Locations (1)

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.

Time frame: Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.